These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 23308242

  • 1. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
    Weingaertner IR, Koutnik S, Ammer H.
    PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
    [Abstract] [Full Text] [Related]

  • 2. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 3. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
    Wells V, Mallucci L.
    Breast Cancer Res; 2009; 11(1):R2. PubMed ID: 19133120
    [Abstract] [Full Text] [Related]

  • 4. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 5. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
    Awasthi S, Hamburger AW.
    J Cell Physiol; 2014 Nov 15; 229(11):1831-41. PubMed ID: 24692179
    [Abstract] [Full Text] [Related]

  • 6. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Nov 15; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 7. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
    von der Heyde S, Bender C, Henjes F, Sonntag J, Korf U, Beißbarth T.
    BMC Syst Biol; 2014 Jun 25; 8():75. PubMed ID: 24970389
    [Abstract] [Full Text] [Related]

  • 8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 Jun 25; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 10. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
    Vijapurkar U, Kim MS, Koland JG.
    Exp Cell Res; 2003 Apr 01; 284(2):291-302. PubMed ID: 12651161
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
    Yang C, Liu Y, Lemmon MA, Kazanietz MG.
    Mol Cell Biol; 2006 Feb 01; 26(3):831-42. PubMed ID: 16428439
    [Abstract] [Full Text] [Related]

  • 14. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
    Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P.
    Mol Cancer Ther; 2005 Feb 01; 4(2):243-55. PubMed ID: 15713896
    [Abstract] [Full Text] [Related]

  • 15. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.
    Breast Cancer Res; 2011 Apr 14; 13(2):R43. PubMed ID: 21492444
    [Abstract] [Full Text] [Related]

  • 16. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.
    Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC.
    J Biol Chem; 2007 Jan 12; 282(2):1479-86. PubMed ID: 17110380
    [Abstract] [Full Text] [Related]

  • 17. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.
    Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG.
    Oncogene; 2002 Jan 03; 21(1):78-86. PubMed ID: 11791178
    [Abstract] [Full Text] [Related]

  • 18. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H, Akita RW, Sliwkowski MX, Maihle NJ.
    Cancer Res; 2001 Jun 01; 61(11):4467-73. PubMed ID: 11389077
    [Abstract] [Full Text] [Related]

  • 19. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
    Chen J, Ren Q, Cai Y, Lin T, Zuo W, Wang J, Lin R, Zhu L, Wang P, Dong H, Zhao H, Huang L, Fu Y, Yang S, Tan J, Lan X, Wang S.
    Biochem Biophys Res Commun; 2018 Jun 18; 501(1):212-219. PubMed ID: 29715459
    [Abstract] [Full Text] [Related]

  • 20. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N, Pust S, Sandvig K.
    Biochim Biophys Acta; 2014 Sep 18; 1843(9):1987-96. PubMed ID: 24747692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.